Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Acquired by Mariner LLC

Mariner LLC raised its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 14.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 142,504 shares of the company's stock after purchasing an additional 17,525 shares during the period. Mariner LLC's holdings in Takeda Pharmaceutical were worth $1,887,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of TAK. QRG Capital Management Inc. grew its holdings in Takeda Pharmaceutical by 16.8% in the 4th quarter. QRG Capital Management Inc. now owns 329,644 shares of the company's stock worth $4,364,000 after buying an additional 47,490 shares in the last quarter. Versant Capital Management Inc acquired a new position in Takeda Pharmaceutical during the 4th quarter worth $26,000. Franklin Resources Inc. bought a new position in shares of Takeda Pharmaceutical in the third quarter worth $244,000. US Bancorp DE increased its holdings in shares of Takeda Pharmaceutical by 21.2% during the fourth quarter. US Bancorp DE now owns 124,332 shares of the company's stock valued at $1,646,000 after purchasing an additional 21,744 shares during the period. Finally, Blue Trust Inc. raised its stake in shares of Takeda Pharmaceutical by 27.0% during the fourth quarter. Blue Trust Inc. now owns 14,430 shares of the company's stock valued at $205,000 after purchasing an additional 3,071 shares in the last quarter. Institutional investors own 9.17% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley raised shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Price Performance

Shares of NYSE:TAK opened at $15.13 on Friday. The stock's 50 day moving average price is $14.70 and its 200 day moving average price is $13.93. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. The stock has a market cap of $48.14 billion, a price-to-earnings ratio of 37.83, a PEG ratio of 0.24 and a beta of 0.39. Takeda Pharmaceutical Company Limited has a 12 month low of $12.58 and a 12 month high of $15.37.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Equities research analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.